Novasol Chemicals has joined forces with Hivest Capital Partners
December 2025 — Novasol Chemicals, a dynamic and rapidly expanding global distributor of specialty chemicals, has entered into a financial partnership with Hivest Capital Partners to support its next phase of growth. The partnership is intended to accelerate Novasol’s international expansion, with a focus on both organic growth and selective acquisitions, further strengthening the company’s position in a highly fragmented market.
Novasol Chemicals is a global specialty chemical distributor with a diversified product portfolio across high-value end markets such as pharmaceuticals; agrochemicals; personal care; coatings, adhesives, sealants and elastomers (CASE); polymers; and energy and environment. Founded in 1997, Novasol has grown into an international chemical distribution platform with operations across Europe, North America and Asia. The company distributes specialty chemicals and ingredients to more than 500 clients in over 50 countries, leveraging a broad product portfolio and strong technical expertise across two main verticals, life sciences and material sciences. In recent years, Novasol has reinforced its organization through the establishment of a seasoned management team and the professionalization of its governance structure. The company has expanded into new geographies, including Turkey and Poland, while strengthening its presence in North America. In parallel, Novasol has launched environmental, social and governance (ESG) initiatives, including more sustainable packaging and logistics practices, as well as enhanced transparency and responsible practices across its supply chain.
Hivest Capital Partners is an independent European private equity firm authorized by the Financial Markets Authority, managing close to US$1.2 billion in assets. The firm invests in mid-sized businesses with revenues generally ranging from US$58 million to US$580 million, supporting management teams through innovative growth strategies and operational performance improvements.
Our role in the transaction
Oaklins’ team in Belgium acted as the exclusive sell-side M&A advisor to the shareholders of Novasol Chemicals in connection with the financial partnership involving Hivest Capital Partners.
François-Xavier Coiffard and Annie Okmez
Shareholders, Novasol Chemicals
Talk to the deal team
Pieter Vanhoudt
Oaklins KBC Securities
Emily Vandewoude
Oaklins KBC Securities
Related deals
Cibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Learn moreGroGlass has been acquired by Apogee Enterprises
Apogee Enterprises, Inc. (Nasdaq: APOG), a leading US provider of architectural building products, services and high-performance coated materials, has acquired GroGlass, a Latvia-based developer and manufacturer of high-performance anti-reflective and UV-protective glass coatings. The acquisition brings GroGlass’ differentiated coating technologies and materials science expertise into Apogee’s performance surfaces segment, broadening its product offering and market reach while expanding its manufacturing and R&D presence in Europe.
Learn moreNextalia has acquired a majority stake in Witapp
Nextalia SGR S.p.A. has acquired a majority stake in Witapp S.r.l., an Italian company specializing in software development for the digitization of healthcare infrastructure. The acquisition strengthens Nextalia’s track record in technology companies serving the public sector and supports its strategy of investing in businesses operating at the intersection of healthcare digitization and the modernization of public services.
Learn more